His early research focused on the epigenetic basis of schizophrenia using neural stem cells to demonstrate a role for the SCZ-risk gene ZNF804a as a gene transcription regulator. During his postdoc, his research focused on the cell-type-specific effects of rapid antidepressants, including ketamine and scopolamine using pharmacogenomic approaches. During his VA Career Development fellowship he worked on human postmortem studies focused on the functional genomics of neuropsychiatric disorders, specifically PTSD and major depression. He published the first genome-wide transcriptomic study of the human PTSD brain (Girgenti MJ, et al. 2021). His research now focuses on genomic studies of the postmortem human brain, combining molecular biology and bioinformatics to understand the neurobiology of major brain and behavioral disorders, including depression, PTSD, and alcohol use disorder.